Evidence map›Paper›PMID 42779575›Full record

ArticlebioRxiv : the preprint server for biology2026

Activation of Pol theta-mediated end joining begins during mitotic commitment.

Connor P McBrine, Ryan B Jensen, Megan C King

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Connor P McBrineDepartment of Cell Biology, Yale School of Medicine, New Haven, CT, 06520, USA.ORCID 0000-0003-1249-1102
Ryan B JensenDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, 06520, USA.ORCID 0000-0002-9844-0789
Megan C KingDepartment of Cell Biology, Yale School of Medicine, New Haven, CT, 06520, USA.ORCID 0000-0002-1688-2226

Funding

Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 1985 to 2026
$85.0M
Skill Development for Diverse Scientific Careers: A New Course Predoctoral Program in Cellular and Molecular BiologyT32GM007223 · NIGMS · YALE UNIVERSITY · PI BASERGA, SUSAN J · 1985 to 2019
$31.0M
Mechanisms of PARPi Resistance in BRCA2 Mutated CancerR01CA270788 · NCI · YALE UNIVERSITY · PI Ryan Brown Jensen · 2022 to 2026
$2.0M
Elucidating Cancer Risk in BRCA2 and RAD51 VariantsR01CA215990 · NCI · YALE UNIVERSITY · PI JENSEN, RYAN BROWN · 2017 to 2021
$1.9M
High Performance Computing Instrumentation for the Yale Center for Genome AnalysisS10OD030363 · OD · YALE UNIVERSITY · PI MANE, SHRIKANT M · 2022 to 2022
$1.2M
NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA215990NCI NIH HHS R01 CA270788NIGMS NIH HHS T32 GM007223NIH HHS S10 OD030363
6 · The paper itself

Abstract

Polymerase theta-mediated end-joining (TMEJ) is a salvage DNA repair pathway that anneals and ligates microhomologies flanking a DNA double-strand break (DSB) downstream of aborted homologous recombination to ensure DSBs are resolved before chromosome segregation. Here, we use a sensitive deep-sequencing approach to identify DSB repair outcomes at an endogenous locus. We observe that TMEJ is impaired by depletion or inhibition of DNA2, a component of the DSB resection machinery. Mechanistically we find that DNA2 deficiency influences TMEJ efficiency by slowing S-phase progression, thereby preventing cells from reaching mitotic commitment at the G2/M transition, when we find that TMEJ is optimally licensed to occur. Further interrogation of the cell cycle regulation of TMEJ reinforces a strict requirement for the mitotic kinase PLK1 in enabling TMEJ at the G2/M transition. We surprisingly find CDK1 to be largely dispensable for TMEJ, but important for a small subset of repair events likely occurring in mitosis. These findings have important implications for modulation of TMEJ in response to cell cycle kinase inhibitors that are in active development as anti-tumor agents.

Identifiers

PMID42779575
PMCPMC13596132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.